# Anthropic is making biotech boasts, but scientists are wary of hype around ‘curing cancer’

- URL: https://talkfuse.com/story/anthropic-is-making-biotech-boasts-but-scientists-are-wary-of-hype-around-curing-cancer/
- Published: 2026-11-06T15:27:39+00:00
- Updated: 2026-11-06T17:09:07+00:00
- Original publisher: New York Post (publisher lean: Right)
- Original article: https://nypost.com/2026/11/06/tech/anthropic-is-making-biotech-boasts-but-scientists-are-wary-of-hype-around-curing-cancer/
- Topics: AI, Business, Companies, Health, Markets, Medicine, Research, Science, Technology, World

## Key points

- Anthropic is investing in biotech and promoting AI’s medical potential.
- No AI-developed drug has full FDA approval.
- Cancer drug development still faces steep clinical trial odds.

## Summary

Anthropic is expanding into biotechnology, opening a Bay Area biology lab, acquiring two biotech startups and partnering with drugmakers as it promotes AI’s potential to speed up medical research. Its chief executive, Dario Amodei, has suggested AI could compress decades of biological progress into five to 10 years, but scientists caution that claims about curing cancer remain unproven.

AI tools are already being used in medicine, including to support personalised treatments, but no AI-developed drug has received full US Food and Drug Administration approval. Only about one in 10 drugs entering human trials reach the market, and for cancer drugs the figure is closer to one in 20. Anthropic says its work is at an early, mostly preclinical stage; researchers say success in people, not lab results, will show whether the technology can deliver.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.